Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (NYSE: MDT) announced the pricing of €6.25 billion in senior notes with varying maturities from 2023 to 2050. The offering includes €1.25 billion of 0.000% notes due 2023 and €1 billion of 1.625% notes due 2050, among others. Proceeds will be utilized to retire existing debt and for general corporate purposes. The offering is expected to close on September 29, 2020. The joint book-running managers include Barclays Bank PLC and Deutsche Bank Aktiengesellschaft.
Medtronic plc (NYSE:MDT) has initiated the ALLEVIATE-HF clinical trial to assess the effectiveness of its Reveal LINQ™ Insertable Cardiac Monitor (ICM) in detecting patients at high risk of worsening heart failure. The study will enroll up to 300 patients across 30 sites in the U.S. over a minimum follow-up period of seven months to three years. The LINQ device wirelessly monitors heart conditions and alerts clinicians of potential heart failure risks, enabling timely interventions. Heart failure affects 6.2 million Americans, emphasizing the importance of this technology in proactive patient management.
Medtronic plc (NYSE:MDT) has achieved FDA Breakthrough Device Designation for its TYRX™ Absorbable Antibacterial Driveline Wrap. This device supports patients with ventricular assist devices (VAD) by minimizing the risk of infection associated with the percutaneous driveline. The wrap releases antimicrobial agents over a minimum of seven days and is designed to be fully absorbed approximately nine weeks post-implantation. The Breakthrough Device Program ensures expedited review and communication from the FDA to facilitate timely access to critical medical technologies.
Medtronic plc (NYSE: MDT) released data from the WRAP-IT study, indicating that the TYRX Absorbable Antibacterial Envelope is cost-effective for patients with elevated infection risks receiving cardiac implantable electronic devices (CIEDs). The ICER of the envelope remains below the recommended threshold of $150,000, demonstrating significant cost-efficiency compared to standard infection prevention methods. Long-term data reveals a 40% reduction in major CIED infections and sustained benefits over three years. This innovation received endorsement from major medical societies and recognition as a top medical innovation for 2020.
Medtronic plc (NYSE: MDT) announced its participation in the Morgan Stanley 18th Annual Global Healthcare Conference, scheduled for September 14, 2020. CEO Geoff Martha will address questions starting at 1:30 p.m. EDT. A live audio webcast will be accessible via Medtronic's investor relations page, with an archived version available post-event. Medtronic, headquartered in Dublin, Ireland, is a leading medical technology company focused on improving healthcare worldwide, employing over 90,000 people in 150+ countries.
Medtronic plc (NYSE: MDT) reported key findings from the PRODIGY study, revealing that opioid-induced respiratory depression (OIRD) occurred in 46% of patients monitored. The study also established the PRODIGY Risk Score, a tool to identify high-risk patients for OIRD, which can lead to longer hospital stays and increased adverse events. This research assessed 1,335 patients across multiple regions, indicating a significant predictive capability for respiratory risks, thus enhancing patient safety during opioid administration.
Medtronic plc (NYSE:MDT) has received FDA approval for an early feasibility study of its Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) system, targeting severe tricuspid regurgitation—a condition affecting over 2 million patients in the U.S. The study follows the recent Breakthrough Device Designation for the TTVR system, aimed at improving treatment access for high-risk patients. Experts express optimism that the trial will enhance understanding of this serious condition and lead to further innovations in therapy.
Medtronic plc (NYSE:MDT) will participate in the Wells Fargo Securities 2020 Virtual Healthcare Conference on September 10, 2020. The event features Karen Parkhill, executive vice president and CFO, answering questions starting at 10:40 a.m. EDT. A live webcast will be accessible through the Investor Events link on the company’s website. An archive will be available later that day. Medtronic, headquartered in Dublin, is a leader in medical technology, employing over 90,000 people globally. It focuses on improving health outcomes worldwide.
Medtronic plc (NYSE:MDT) has received FDA approval for its MiniMed™ 770G hybrid closed-loop insulin pump system, enhancing diabetes management for children as young as 2. This advanced system includes SmartGuard™ technology with smartphone connectivity, allowing caregivers to monitor real-time glucose levels and share data with clinicians. The MiniMed 770G aims to improve clinical outcomes based on evidence from a clinical study, indicating no severe hypoglycemia or device-related adverse events. Orders for the system will begin in the United States this week.
DUBLIN, Aug. 29, 2020 – Medtronic (NYSE: MDT) announced positive clinical trial results for its Arctic Front™ Advance Cryoballoon and Freezor® MAX Catheter. In the STOP-AF First trial, cryoablation proved superior to antiarrhythmic drugs (AAD) for treating recurrent symptomatic paroxysmal atrial fibrillation (PAF), with a 75% success rate compared to 45% for AAD. The Cryo-FIRST trial further showed significant quality of life improvements with the cryoablation system. The Arctic Front Advance is FDA-approved for treating symptomatic recurrent persistent AF, expanding treatment options for patients.
